Sign in Subscribe
Financial statements

ADC Therapeutics SA Raises $60 Million in Private Placement Funding

Strategic Insights

— 2 min read

ADC Therapeutics SA, a biotechnology company focused on the development and commercialization of innovative cancer therapies, has filed a Form 8-K with the US Securities and Exchange Commission (SEC) announcing the signing of a securities purchase agreement for a private placement funding of $60 million. The funding round is expected to close on October 27, 2025, subject to customary closing conditions.

Under the agreement, the Company will issue 11,250,000 common shares and 3,846,153 pre-funded warrants to purchase common shares at a price of $4.00 and $3.90 per share, respectively. The pre-funded warrants will be exercisable at any time after their original issuance until the tenth anniversary of their original issuance. The exercise price per common share purchasable upon the exercise of the pre-funded warrants is CHF 0.08 per share, subject to customary adjustments. The Company has agreed to file a registration statement within 30 business days to register the resale of the common shares sold in the private placement and the common shares issuable upon exercise of the pre-funded warrants.

ADC Therapeutics has also issued a press release announcing preliminary net product revenues from sales of ZYNLONTA for the quarter ended September 30, 2025, and preliminary cash and cash equivalents as of September 30, 2025. However, the financial results are preliminary and unaudited and reflect management's estimated financial results. The Company's actual financial results for the quarter have not yet been finalized by management or audited or reviewed by its independent auditors.

Key Takeaways:

  • ADC Therapeutics SA has signed a securities purchase agreement for a private placement funding of $60 million, with the funding round expected to close on October 27, 2025.
  • The Company will issue 11,250,000 common shares and 3,846,153 pre-funded warrants to purchase common shares at prices of $4.00 and $3.90 per share, respectively.
  • The pre-funded warrants will be exercisable at any time after their original issuance until the tenth anniversary of their original issuance.
  • The exercise price per common share purchasable upon the exercise of the pre-funded warrants is CHF 0.08 per share, subject to customary adjustments.
  • ADC Therapeutics has agreed to file a registration statement within 30 business days to register the resale of the common shares sold in the private placement and the common shares issuable upon exercise of the pre-funded warrants.
  • The Company has issued preliminary financial results for the quarter ended September 30, 2025, but the figures are unaudited and subject to change.
  • ADC Therapeutics has a history of developing innovative cancer therapies, including ZYNLONTA, which has shown promising results in clinical trials.

Statistics:

  • $60 million: The amount of private placement funding signed by ADC Therapeutics SA.
  • 11,250,000: The number of common shares to be issued by the Company.
  • 3,846,153: The number of pre-funded warrants to be issued by the Company.
  • $4.00: The price per common share at which the Company will issue common shares.
  • $3.90: The price per pre-funded warrant at which the Company will issue pre-funded warrants.
  • CHF 0.08: The exercise price per common share purchasable upon the exercise of the pre-funded warrants.
  • October 27, 2025: The expected closing date of the private placement funding.

Sources:

  • Form 8-K, filed with the US Securities and Exchange Commission on October 14, 2025.
  • Press release dated October 13, 2025.
  • Corporate presentation dated October 13, 2025.

Read more